Fresenius Kabi steps into the Canadian market for adalimumab with Idacio.
Fresenius Kabi has launched an adalimumab injectable biosimilar (Idacio) in Canada, the company said in a statement. The product, which marks Fresenius Kabi’s first North American biosimilar launch, is approved for all 12 indications of the reference product, Humira, in Canada.
Those indications are rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, adult and adolescent hidradenitis suppurativa, adult and pediatric Crohn disease, ulcerative colitis, adult noninfectious uveitis, and pediatric chronic noninfectious anterior uveitis. Health Canada issued approval for the biosimilar on October 30, 2020.
Fresenius Kabi’s global headquarters are in Bad Homburg, Germany, although it operates a Canada division that is managing this launch.
The Canada launch marks the second for an adalimumab biosimilar this week. Sandoz launched Hyrimoz, also an injectable biosimilar, which is indicated for 9 of 12 indications of the originator product.
Idacio has been available in Europe since 2019, although in a low-concentration formulation that faces strong competition from other adalimumab biosimilars and a high-concentration version of adalimumab introduced by AbbVie, the originator company.
Fresenius Kabi Pipeline
In its pipeline, Fresenius Kabi is developing a tocilizumab biosimilar, referencing Actemra, which is for the treatment of severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. The company also is developing a pegfilgrastim biosimilar, a supportive care product for the treatment of patients undergoing chemotherapy and vulnerable to infection.
Canada is considered an increasingly fertile territory for biosimilar distribution, given the country's embrace of these lower-cost medicines through the development of policies that give preference to biosimilar use. Earlier this month, Celltrion received Health Canada approval for a subcutaneous infliximab biosimilar (Remsima) for the treatment of rheumatoid arthritis.
Also, in November, Alberta, the fourth largest province in Canada, reported early success with a biosimilar switching program. According to Graham Statt, assistant deputy minister of the Pharmaceutical and Supplementary Benefits Division for Alberta Health, 30% of patients receiving infliximab in Alberta had switched to a biosimilar since December 2019. And in general, the province had succeeded in switching 16% of patients from 7 costlier reference products. Alberta is aiming for biosimilar savings approaching $200 million over the next 4 years.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.